raclopride and Cognitive-Dysfunction

To assess the impact of reducing the dose of antipsychotics on cognition and dopaminergic D. Open-label prospective PET [. A tertiary care center outpatient setting.. Thirty-seven clinically stable participants with schizophrenia or schizoaffective disorder, aged 50 years or greater, and having been treated with olanzapine or risperidone monotherapy at the same dose for at least 6 months.. Gradual reduction in their olanzapine or risperidone daily dose of up to 40%.. Clinical and cognitive assessments, and [. Reducing the antipsychotic dose resulted in an increase in D. Our findings suggest that optimizing D

Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cognitive Dysfunction; Corpus Striatum; Female; Humans; Male; Middle Aged; Olanzapine; Positron-Emission Tomography; Psychotic Disorders; Raclopride; Receptors, Dopamine D2; Risperidone; Schizophrenia